Skip to main content
Top
Published in: Endocrine Pathology 4/2018

01-12-2018

Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis

Authors: Daniel Lubin, Ezra Baraban, Amanda Lisby, Sahar Jalali-Farahani, Paul Zhang, Virginia Livolsi

Published in: Endocrine Pathology | Issue 4/2018

Login to get access

Abstract

There is evidence that programmed death-ligand 1 (PD-L1) is expressed by thyroid follicular epithelium in thyroiditis, but the role of PD-L1 in papillary thyroid carcinoma (PTC) is poorly understood. We aimed to determine whether (1) the presence of background chronic lymphocytic thyroiditis (CLT) or Hashimoto thyroiditis (HT) influenced the expression of PD-L1 in benign follicular epithelium or in PTC and (2) if PD-L1 expression in PTC persisted with lymph node metastasis. We performed immunohistochemistry (IHC) for PD-L1 on formalin-fixed paraffin-embedded tissues. We first studied five cases of unremarkable thyroid, five cases of CLT, and five cases of HT without carcinoma. We subsequently performed PD-L1 IHC on ten cases of PTC arising in normal thyroid, ten cases of PTC arising in CLT, and ten cases of PTC arising in HT. Whenever available, we evaluated corresponding synchronous lymph node metastases from all cases for PD-L1 expression. PD-L1 expression was increased (10–90%) in all five cases of HT, only minimal expressed (1–5%) in two of five cases of CLT, and not expressed in five cases of unremarkable thyroid. PTC arising in normal thyroid or CLT nearly uniformly lacked PD-L1 expression. In contrast, PTC arising in HT demonstrated significant PD-L1 expression, which persisted in corresponding lymph node metastases. Background non-neoplastic follicular epithelium in the HT cases also demonstrated PD-L1 expression. Thyroid follicular epithelium in HT demonstrates increased PD-L1 expression, and PTC arising in a background of HT shows increased PD-L1 expression, which is retained with metastasis.
Literature
1.
go back to reference Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM (2017) Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. Jama 317(13):1338, 1348.CrossRef Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM (2017) Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. Jama 317(13):1338, 1348.CrossRef
2.
go back to reference Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP (1999) Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: Impact on presentation, management, and outcome. Surgery 126(6):1070–1077.CrossRef Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP (1999) Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: Impact on presentation, management, and outcome. Surgery 126(6):1070–1077.CrossRef
3.
go back to reference Liu FH, Kuo SF, Hsueh C, Chao TC, Lin JD (2015) Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. J Surg Oncol 1:149–154.CrossRef Liu FH, Kuo SF, Hsueh C, Chao TC, Lin JD (2015) Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. J Surg Oncol 1:149–154.CrossRef
4.
go back to reference Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26(8):879–885.CrossRef Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26(8):879–885.CrossRef
5.
go back to reference Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21(11):1–23. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21(11):1–23.
6.
go back to reference Teng MWL, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers basedon T-cell infiltration and PD-L1. Cancer Res 75(11):2139–2145.CrossRef Teng MWL, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers basedon T-cell infiltration and PD-L1. Cancer Res 75(11):2139–2145.CrossRef
7.
go back to reference Wang DY, Johnson DB, Davis EJ (2018) Toxicities Associated With PD-1/PD-L1 Blockade. Cancer J 24(1):36–40.CrossRef Wang DY, Johnson DB, Davis EJ (2018) Toxicities Associated With PD-1/PD-L1 Blockade. Cancer J 24(1):36–40.CrossRef
8.
go back to reference Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, Maruyama H, Fujisawa Y, Matsuya T, Fujimoto M, Yamamoto A (2017) Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J Dermatol 44(2):117–122.CrossRef Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, Maruyama H, Fujisawa Y, Matsuya T, Fujimoto M, Yamamoto A (2017) Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J Dermatol 44(2):117–122.CrossRef
9.
go back to reference Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N (2018) Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115 (August 2017):71–74.CrossRef Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N (2018) Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115 (August 2017):71–74.CrossRef
10.
go back to reference Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish PG (2016) Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget 7(22):32318–32328.CrossRef Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish PG (2016) Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget 7(22):32318–32328.CrossRef
11.
go back to reference Kwok G, Yau TCC, Chiu JW, Tse E, Kwong Y (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777–2789.CrossRef Kwok G, Yau TCC, Chiu JW, Tse E, Kwong Y (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777–2789.CrossRef
12.
go back to reference Hsieh MS, Chou YH, Yeh SJ, Chang YL (2015) Papillary-cystic pattern is characteristic in mammary analogue secretory carcinomas but is rarely observed in acinic cell carcinomas of the salivary gland. Virchows Arch 467(2):145–153.CrossRef Hsieh MS, Chou YH, Yeh SJ, Chang YL (2015) Papillary-cystic pattern is characteristic in mammary analogue secretory carcinomas but is rarely observed in acinic cell carcinomas of the salivary gland. Virchows Arch 467(2):145–153.CrossRef
13.
go back to reference Fu G, Polyakova O, MacMillan C, Ralhan R, Walfish PG (2017) Programmed Death-Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features. EBioMedicine 18:50–55.CrossRef Fu G, Polyakova O, MacMillan C, Ralhan R, Walfish PG (2017) Programmed Death-Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features. EBioMedicine 18:50–55.CrossRef
14.
go back to reference Ahn S, Kim TH, Kim SW, Ki CS, Jang HW (2017) Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 24(2):97–106.CrossRef Ahn S, Kim TH, Kim SW, Ki CS, Jang HW (2017) Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 24(2):97–106.CrossRef
15.
go back to reference Rosenbaum MW, Gigliotti BJ, Pai SI, Parangi S, Wachtel H, Mino-Kenudson M, Gunda V, Faquin WC (2018) PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. Endocr Pathol 29:59–67.CrossRef Rosenbaum MW, Gigliotti BJ, Pai SI, Parangi S, Wachtel H, Mino-Kenudson M, Gunda V, Faquin WC (2018) PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. Endocr Pathol 29:59–67.CrossRef
16.
go back to reference An HJ, Ko GH, Lee JH, Lee JS, Kim DC, Yang JW, Kim MH, Kim JP, Jung EJ, Song DH (2018) Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma. J Pathol Transl Med 52(1):9–13.CrossRef An HJ, Ko GH, Lee JH, Lee JS, Kim DC, Yang JW, Kim MH, Kim JP, Jung EJ, Song DH (2018) Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma. J Pathol Transl Med 52(1):9–13.CrossRef
17.
go back to reference Zwaenepoel K, Jacobs J., de Meulenaere A., Silence K., Smits E., Siozopoulou V., Hauben E., Rolfo C., Rottey S., Pauwels P. (2017) CD70 and PD-L1 in anaplastic thyroid cancer – promising targets for immunotherapy. Histopathology 71:357–365.CrossRef Zwaenepoel K, Jacobs J., de Meulenaere A., Silence K., Smits E., Siozopoulou V., Hauben E., Rolfo C., Rottey S., Pauwels P. (2017) CD70 and PD-L1 in anaplastic thyroid cancer – promising targets for immunotherapy. Histopathology 71:357–365.CrossRef
18.
go back to reference Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, Fauci AS (2008) The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 181(10):6738–6746.CrossRef Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, Fauci AS (2008) The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 181(10):6738–6746.CrossRef
19.
go back to reference Cunha LL, Marcello MA, Morari EC, Nonogaki S, Conte FF, Gerhard R, Soares FA, Vassallo J, Ward LS (2013) Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocr Relat Cancer 20(1):103–110.CrossRef Cunha LL, Marcello MA, Morari EC, Nonogaki S, Conte FF, Gerhard R, Soares FA, Vassallo J, Ward LS (2013) Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocr Relat Cancer 20(1):103–110.CrossRef
20.
go back to reference McLaughlin JF, et al. (2014) Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). J Clin Oncol 32(15_suppl):8064. McLaughlin JF, et al. (2014) Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). J Clin Oncol 32(15_suppl):8064.
21.
go back to reference Parra ER, Villalobos P, Mino B, Rodriguez-Canales J (2018) Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26(2):83–93.PubMed Parra ER, Villalobos P, Mino B, Rodriguez-Canales J (2018) Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26(2):83–93.PubMed
22.
go back to reference Bai Y, et al. (2017) PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. Diagn Pathol 12(1):1–8.CrossRef Bai Y, et al. (2017) PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. Diagn Pathol 12(1):1–8.CrossRef
23.
go back to reference Shi R, Qu N, Luo TX, Xiang J, Liao T, Sun GH, Wang Y, Wang YL, Huang CP, Ji QH (2017) Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence. Thyroid 27(4):537–545.CrossRef Shi R, Qu N, Luo TX, Xiang J, Liao T, Sun GH, Wang Y, Wang YL, Huang CP, Ji QH (2017) Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence. Thyroid 27(4):537–545.CrossRef
Metadata
Title
Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis
Authors
Daniel Lubin
Ezra Baraban
Amanda Lisby
Sahar Jalali-Farahani
Paul Zhang
Virginia Livolsi
Publication date
01-12-2018
Publisher
Springer US
Published in
Endocrine Pathology / Issue 4/2018
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-018-9540-9

Other articles of this Issue 4/2018

Endocrine Pathology 4/2018 Go to the issue